As more women (and scientists) turn their attention to improving their quality of life during and after menopause, Anderson is sharing the subtle but significant changes GLP-1s are bringing to her day-to-day life in this installment of " On My Weigh ." The Weigh-in Name: Jacqueline Anderson Age: 42 The method: Semaglutide, 2.5 milligrams, then tirzepatide, 2 milligrams The goal: My goal was to use as little medication as possible but still get the benefits
To qualify, you should have a body mass index (BMI) of at least 30 (obese) or 27 (overweight) with a weight-related health condition
Initial research is highly concerning that these medications have side effects that need further research before widespread drug administration and adoption, significantly decrease muscle mass, and can cause significant weight gain after stopping
BMI is one tool used to decide who might benefit from taking a GLP-1 RA for weight loss
Based on the current situation, Novartis and Eli Lilly are expected to dominate the majority of the market in the coming years
EMA and the Heads of Medicines Agencies (HMA), through the Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG), have issued recommendations to tackle shortages of the glucagon-like peptide-1 (GLP-1) receptor agonists Ozempic (semaglutide), Saxenda (liraglutide), Trulicity (dulaglutide) and Victoza (liraglutide)
